A Phase 1 interventional study of Stereotactic Radiosurgery using the Novalis Tx in Prostate Cancer, sponsored by San Diego Radiosurgery. Status unknown at 1 site in United States. Open to male participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2015-11-18.
Sponsored by San Diego Radiosurgery · Phase 1, Interventional, and Treatment
The purpose of this trial is to evaluate a short course of very focused (stereotactic) external beam radiation therapy for the treatment of early stage prostate cancer.
The investigators will gather scientific information about the tolerance and side effects this type of radiation. The investigators will then compare these results with those of standard 8 week course of external beam radiation therapy to see if this study treatment is equally or more effective in treating prostate cancer.
6,367 studies on the registry are indexed under Prostatic Neoplasms; 1,397 are open to participants now.
This study's planned enrollment of 50 is below the median of 58 across 4,821 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →This is the only study on the registry with San Diego Radiosurgery as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Single arm study using the Novalis Tx to perform radiosurgery to treat low grade prostate cancer.
Radiation: Stereotactic Radiosurgery using the Novalis Tx
Five treatments given every other day.
Also known as: Novalis Tx, Novalis
PSA decline measured through laboratory testing.
Time frame: One month following radiosurgery through 5 year follow up
Quality of life in relation to urinary, bowel and sexual function. Measured through a questionnaire at each follow up visit.
Time frame: One month following radiosurgery through 5 years follow up.
This study is status unknown, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.